Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPGUN: Topical sirolimus for lingual microcystic lymphatic malformations
2019-001530-33Phase 2Active
- Sponsor
- CHRU Tours
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sirolimus in lingual microcystic lymphatic malformation (MLM) (2 arms), sponsored by CHRU Tours. Started Apr 2019; status: active.
02
Drugs
sirolimus
03
Conditions
lingual microcystic lymphatic malformation (MLM)
Beyond the preview
Go deeper on 2019-001530-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001530-33.